" class="no-js "lang="en-US"> Tatjana Naranda - Medtech Alert
Sunday, September 14, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Tatjana Naranda

Tatjana Naranda

About Tatjana Naranda

Accomplished senior level executive, with twenty years experience in pharmaceutical industry. Strategic leader with strong background in science with focus on innovation, strategy and applications in the biotechnological industry. Successful track record in business and corporate development (including licensing, M&A and alliance management) and operations.

Related Story

Uncategorized

 Ferrer Launches Third Edition of Ferrer 4 Future (F4F) Program | Pharmtech Focus

Ferrer Launches Third Edition of Ferrer 4 Future (F4F) Program

June 17 2021

Ferrer, a privately-held Spanish pharmaceutical company who aims to make a positive impact in society, […]